Cargando…

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis

OBJECTIVE: This study aims to compare the efficacy and safety of different poly (ADP-ribose) polymerase (PARP) inhibitors in patients with ovarian cancer through a network meta-analysis to support clinical treatment choices. METHODS: The Cochrane Library, PubMed, Embase, Science Citation Index, Chin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Jing, Ou, Shunlong, Wei, Hua, Qin, Xiaoli, Jiang, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213680/ https://www.ncbi.nlm.nih.gov/pubmed/35756600 http://dx.doi.org/10.3389/fonc.2022.815265

Ejemplares similares

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
por: Ni, Jing, et al.
Publicado: (2021)

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
por: Dong, Ruihong, et al.
Publicado: (2023)

Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer
por: Sha, Huanhuan, et al.
Publicado: (2021)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021)

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014)

The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma
por: Pletcher, Jerred P., et al.
Publicado: (2021)

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China
por: Ni, Jing, et al.
Publicado: (2022)

RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair
por: Gou, Rui, et al.
Publicado: (2022)

Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma
por: Magalhães, Denise, et al.
Publicado: (2022)

Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.
por: Nagao, M, et al.
Publicado: (1991)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)

RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015)

Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
por: Yang, Yingzhu, et al.
Publicado: (2020)

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
por: Plummer, R
Publicado: (2011)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Current status of poly(ADP-ribose) polymerase inhibitors and future directions
por: Ohmoto, Akihiro, et al.
Publicado: (2017)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
por: Singh, Bijay, et al.
Publicado: (2020)

Role of poly(ADP-ribose) polymerases in male reproduction
por: Celik-Ozenci, Ciler, et al.
Publicado: (2013)

Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells
por: Nakamura, Kentaro, et al.
Publicado: (2020)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
por: Zhang, Jingsong
Publicado: (2014)

Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models
por: Ordway, Gregory A, et al.
Publicado: (2017)

Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
por: Hastak, Kedar, et al.
Publicado: (2017)

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide
por: Badawy, Abdulla A.-B.
Publicado: (2020)

Effective natural inhibitors targeting poly ADP-ribose polymerase by computational study
por: Zhong, Sheng, et al.
Publicado: (2021)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP-ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells
por: FENG, XIAOXING, et al.
Publicado: (2012)

Stability of centrosome numbers in poly(ADP-ribose) polymerase-1- and poly(ADP-ribose) glycohydrolase-deficient mouse ES cells
por: Ogino, Hideki, et al.
Publicado: (2004)

Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring
por: Orleni, Marco, et al.
Publicado: (2023)

Targeting poly(ADP-ribose) polymerase activity for cancer therapy
por: Mégnin-Chanet, Frédérique, et al.
Publicado: (2010)

Lipoxygenases and Poly(ADP-Ribose) Polymerase in Amyloid Beta Cytotoxicity
por: Strosznajder, Joanna B., et al.
Publicado: (2011)

Analysis of Poly(ADP-Ribose) Polymerases in Arabidopsis Telomere Biology
por: Boltz, Kara A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oahim2ab8crrarifnm3oce8n00